Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Brahmi

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
The Oncologist|June 26, 2020
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series AnalysisGiacomo Giulio Baldi, Mehdi Brahmi, Salvatore Lo Vullo, et al.
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
International Journal of Cancer|September 29, 2025
Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decadeMathilde Reich, Derek Dinart, Hélène Bellio, et al.
British Journal of Cancer|October 13, 2017
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcomaCarmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, et al.
Cancer Medicine|June 3, 2026
Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real-Life National Setting Over a DecadeColine Ducrot, Derek Dinart, Maeva Bonneau, et al.
The Lancet. Oncology|July 10, 2023
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trialJean-Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
The Journal of Pathology. Clinical Research|February 17, 2022
Intra- and extra-cranial BCOR-ITD tumours are separate entities within the BCOR-rearranged familyYassine Bouchoucha, Arnault Tauziède-Espariat, Arnaud Gauthier, et al.
Genes, Chromosomes & Cancer|January 26, 2022
Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosisNicolas Macagno, Daniel Pissaloux, Arnaud de la Fouchardière, et al.
European Radiology|August 18, 2022
Prognostic factors of the synovial sarcoma of the extremities: imaging does matterMickael Tordjman, Charles Honoré, Amandine Crombé, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
The Oncologist|June 26, 2020
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series AnalysisGiacomo Giulio Baldi, Mehdi Brahmi, Salvatore Lo Vullo, et al.
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
International Journal of Cancer|September 29, 2025
Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decadeMathilde Reich, Derek Dinart, Hélène Bellio, et al.
British Journal of Cancer|October 13, 2017
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcomaCarmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, et al.
Cancer Medicine|June 3, 2026
Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real-Life National Setting Over a DecadeColine Ducrot, Derek Dinart, Maeva Bonneau, et al.
The Lancet. Oncology|July 10, 2023
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trialJean-Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
The Journal of Pathology. Clinical Research|February 17, 2022
Intra- and extra-cranial BCOR-ITD tumours are separate entities within the BCOR-rearranged familyYassine Bouchoucha, Arnault Tauziède-Espariat, Arnaud Gauthier, et al.
Genes, Chromosomes & Cancer|January 26, 2022
Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosisNicolas Macagno, Daniel Pissaloux, Arnaud de la Fouchardière, et al.
European Radiology|August 18, 2022
Prognostic factors of the synovial sarcoma of the extremities: imaging does matterMickael Tordjman, Charles Honoré, Amandine Crombé, et al.
Pageof 8